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See Article, pages 141–147The immune system is build on the basis of genetic and epige-
netic factors, and shaped by constant and repeated internal and
external challenges. Autoimmune disease appears to arise as a
consequence of unknown external triggers in a susceptible host.
Susceptibility develops on a predetermined genetic background
[1], and is probably inﬂuenced by multiple environmental factors
and life events such as infections. Once clinically apparent auto-
immune disease has developed, the predisposition is so strong
that cure is very rare indeed. This applies to such diverse autoim-
mune diseases as multiple sclerosis [2], lupus [3], type 1 diabetes
[4] or rheumatoid arthritis [5]. To an immunologist, it does there-
fore not come as a surprise that autoimmune hepatitis (AIH)
behaves similarly, and that most patients require life-long treat-
ment as reported in this issue of the Journal [6].
However, this message does come as a surprise to the patient.
And it often also comes as a surprise to the treating hepatologist.
Patients want diseases to disappear, and as physicians we like to
share our patients’ optimism. In case of autoimmune hepatitis,
the mostly excellent response to immunosuppressive therapy
[7] and the usually asymptomatic course of AIH in remission
make it all the more tempting to try and withdraw treatment.
Furthermore, the possible side effects of immunosuppressive
drug treatment make a trial of treatment withdrawal even more
attractive. Like in all other chronic diseases, it is difﬁcult to know
which drug schedule and which dosages should be applied and
for how long. The published guidelines give only very little help
in these decisions and the data on which these are based are
scarce [8–10]. The study by van Gerven et al. [6] describing the
relapse rate in a large group of patients observed in various cen-
ters in the Netherlands is therefore a very welcome addition to
the literature, and the message is sobering: even when being
selective in choosing patients in whom a trial of treatment with-
drawal is undertaken, the vast majority relapse, and very few
patients indeed maintain remission without continued therapy.
Relapse is usually early, but may sometimes be late, and a longer
observation period in this study might have increased this ﬁgure
even further.Journal of Hepatology 20
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Open access under CC BY-NC-ND license.The study is based on a retrospective analysis of a national
registry, and therefore has a number of almost inevitable meth-
odologically weak points. Most importantly, parameters consid-
ered essential before trying to stop treatment were missing in
many patients. Only 51% of these patients had received measure-
ment of their IgG levels, and only 18% had received a liver biopsy
prior to reduction of immunosuppression. IgG levels in particular
are essential in deﬁning remission [11], and only patients with
repeatedly normal IgG can be considered to be in stable
remission [12], thus potentially qualifying for a trial of drug
withdrawal. Furthermore, the time in remission of patients
withdrawn from treatment was in some patients shorter than
generally recommended. In addition, almost half of these patients
still had dual therapy (steroids plus azathioprine) when
treatment withdrawal was started, while most textbooks and
treatment guidelines [8] recommend stable remission on mono-
therapy (usually azathioprine) before trying to taper out all
treatment. Finally, autoantibody testing was incomplete, and
the given information limited: patients were apparently not
tested for SLA/LP antibodies, and the number of LKM-positive
patients is not shown. Both autoantibodies have been described
as predictors of relapse [13], and most specialists would recom-
mend life-long treatment in patients positive for either of these
two characteristic autoantibodies.
At the same time, the study has some important strengths not
to be found in earlier reports on this subject. The study is based
on a large patient population of altogether 844 AIH cases col-
lected from 21 Dutch treatment centers, mostly not highly spe-
cialized referral centers, and therefore is likely to reﬂect
everyday practice quite well. It is therefore particularly sobering
to see that out of this large group of patients so few could safely
been withdrawn of all treatment: treatment withdrawal was only
attempted in a selected 16% of the whole group; almost half of
these developed a ﬂare while still on a reduced dose of drugs
and only 1.7% of the overall patient group ended up without
drugs. The conclusion that with very few exceptions AIH is a
chronic disease requiring long-term and mostly life-long treat-
ment is thus very convincing.
Can we predict in whom withdrawal of immunosuppressive
treatment might be successful? There are hints in this study,
and there are hints in the literature [13–17]. New in the present
study is that younger age correlated with relapse, as did the pres-
ence of extra-hepatic autoimmune disease. Both ﬁndings are not
surprising. Pediatric hepatologists have always recommended13 vol. 58 j 5–7
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Fig. 1. Possible treatment algorithm for treatment decisions in AIH. After information and education of the patient, several possibilities can be considered when
sustained remission on monotherapy is established: (1) A trial of drug withdrawal can be undertaken after having informed the patient of a high probability of relapse. (2)
Liver biopsy can be performed and results can be used to inﬂuence further treatment, especially in patients <45 years old and with concomitant autoimmune diseases. (3) In
older patients or those unwilling to undergo liver biopsy or experimental treatment withdrawal, immunosuppressive therapy can be continued.
Editorialthat immunosuppression should not be stopped in children with
AIH [18], and that ﬁrst manifestation of the disease in childhood
usually requires life-long therapy. The co-existence of other auto-
immune diseases in the same patient is likely to indicate a stron-
ger susceptibility for autoimmunity. Scientiﬁcally, these ﬁndings
may not come as a surprise, but clinically, they can be very help-
ful in the daily management of AIH patients, as they warn us to
be particularly hesitant with a trial of drug withdrawal in these
two patient groups. It should also warrant an active search for
concomitant autoimmune diseases.
Even if drug withdrawal appears to be successful and the
patient is in biochemical remission more than 1 year later, the
patient remains an AIH patient: late relapse can occur. Relapse
more than 20 years after successful drug withdrawal has been
described in the literature [19], and we have observed similar
cases. Frequent laboratory controls will be necessary in the ﬁrst
years after treatment withdrawal [1], and regular (at least yearly)
testing of both transaminases and IgG levels thereafter is essen-
tial. The threshold to reinstitute immunosuppression should be
low. In particular so, because AIH may run a subclinical course,
and cirrhosis may progress without symptoms [1] – this prevent-
able complication should not occur. Attention should be paid to
rising IgG levels even within the normal limit, as a clear increase6 Journal of Hepatology 2for example from low normal to high normal values is likely to
indicate renewed disease activity.
What are the scientiﬁc questions arising from this study? We
should try to understand better the underlying susceptibility fac-
tors that cause AIH, and that might predict who has a chance of a
stable drug-free remission. We should try to identify predictors
beyond those discussed in this study: disease presentation, time
to remission, drug-dosage required for remission induction, auto-
antibody proﬁles and titres, IgG levels and ALT levels, including
variations in the normal range, histological features at presenta-
tion and during treatment, remission duration, etc. In addition to
these more biological factors, we need to address the psycholog-
ical features of managing this chronic disease: compliance with
the recommended treatment was recently shown to be an impor-
tant factor [20], and treatment adherence in a chronic disease
requiring daily medication with potentially toxic drugs may be
very difﬁcult. In managing patients wishing to withdraw treat-
ment, different approaches may be appropriate and should be
adapted to the individual wishes and fears of the patient
(Fig. 1). Textbooks and guidelines [6,8–10] recommend liver
biopsy prior to a trial of treatment withdrawal, and no such trial
if the biopsy shows relevant inﬂammatory activity (usually a
hepatitis activity index (HAI-Score) of 3 or more).013 vol. 58 j 5–7
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However, in daily practice we often take another approach
after careful discussion with the patient: as most patients
strongly wish to try treatment withdrawal, and as we prefer to
undertake such a trial under our supervision rather than the
patient doing it secretly (or not coming back), we discuss such
a trial after a minimum of 3 years of stable remission. We
strongly discourage such a trial in patients requiring dual immu-
nosuppression or experiencing ﬂares during maintenance ther-
apy, as failure is certain. In all other patients, we discuss the
option of biopsy or a trial of treatment withdrawal without
biopsy, and insist on close monitoring. The majority of patients
opt for a trial of treatment withdrawal without biopsy. In most
patients, relapse tends to occur early, and if treatment with-
drawal in undertaken slowly and stepwise, relapse occurs gradu-
ally. As soon as a relapse is deﬁnite (in some patients this may
require biopsy to demonstrate relapse beyond doubt), immuno-
suppression is reinstituted, usually with a short course of dual
therapy, going back to monotherapy within 3 months. The
approach may be less scientiﬁc, but very effective: we ﬁnd that
patient compliance is greatly improved by such a trial, and the
acceptance for a long-term, usually life-long immunosuppression
at the lowest effective dose is greatly enhanced after such a fail-
ure of treatment withdrawal. The most important message is, as
clearly shown by the present study: AIH is a chronic disease,
no matter how acute the ﬁrst presentation, close medical super-
vision is essential, and the vast majority of patients require
permanent treatment. Communicating the high probability of a
long-term, perhaps life-long need for immunosuppressive medi-
cation early on when diagnosis is established may not please the
patient but ultimately will help develop a trusting relationship
between patient and physician [21]. Assisting the patient to
accept this need, ﬁnding the lowest effective dose of the drugs
tolerated best by this individual patient and motivation for the
necessary drug-adherence will improve life expectancy, long-
term outcome and patient satisfaction.Conﬂict of interest
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